WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406482
Description: CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer.
MedKoo Cat#: 406482
Chemical Formula: C26H27F4N7O2
Exact Mass: 545.21624
Molecular Weight: 545.53189
Elemental Analysis: C, 57.24; H, 4.99; F, 13.93; N, 17.97; O, 5.87
CNX-2006, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and SDS documents are available in one week after order is received.
Synonym: CNX2006; CNX 2006; CNX-2006.
IUPAC/Chemical Name: N-(3-((2-((4-((1-(2-fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide
InChi Key: BFSRTTWIPACGMI-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H27F4N7O2/c1-3-23(38)33-16-5-4-6-17(11-16)34-24-20(26(28,29)30)13-31-25(36-24)35-21-8-7-18(12-22(21)39-2)32-19-14-37(15-19)10-9-27/h3-8,11-13,19,32H,1,9-10,14-15H2,2H3,(H,33,38)(H2,31,34,35,36)
SMILES Code: C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(NC4CN(CCF)C4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O
The following data is based on the product molecular weight 545.53189 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
CNX-2006 is a Me-Too version of CO-1686, which structures are compared as below: